Format

Send to

Choose Destination
BJU Int. 2016 Apr;117(4):576-83. doi: 10.1111/bju.13310. Epub 2015 Oct 6.

A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

Author information

1
Department of Urology, University Hospital Zürich, Zürich, Switzerland.
2
Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
3
Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
5
Department of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
6
Department of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland.
7
Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany.

Abstract

OBJECTIVE:

To assess the value of a positive family history (FH) as a risk factor for prostate cancer incidence and grade among men undergoing organised prostate-specific antigen (PSA) screening in a population-based study.

SUBJECTS AND METHODS:

The study cohort comprised all attendees of the Swiss arm of the European Randomised Study of Screening for Prostate Cancer (ERSPC) with systematic PSA level tests every 4 years. Men reporting first-degree relative(s) diagnosed with prostate cancer were considered to have a positive FH. Biopsy was exclusively PSA triggered at a PSA level threshold of 3 ng/mL. The primary endpoint was prostate cancer diagnosis. Kaplan-Meier and Cox regression analyses were used.

RESULTS:

Of 4 932 attendees with a median (interquartile range, IQR) age of 60.9 (57.6-65.1) years, 334 (6.8%) reported a positive FH. The median (IQR) follow-up duration was 11.6 (10.3-13.3) years. Cumulative prostate cancer incidence was 60/334 (18%, positive FH) and 550/4 598 (12%, negative FH) [odds ratio 1.6, 95% confidence interval (CI) 1.2-2.2, P = 0.001). In both groups, most prostate cancer diagnosed was low grade. There were no significant differences in PSA level at diagnosis, biopsy Gleason score or Gleason score on pathological specimen among men who underwent radical prostatectomy between both groups. On multivariable analysis, age (hazard ratio [HR] 1.04, 95% CI 1.02-1.06), baseline PSA level (HR 1.13, 95% CI 1.12-1.14), and FH (HR 1.6, 95% CI 1.24-2.14) were independent predictors for overall prostate cancer incidence (all P < 0.001). Only baseline PSA level (HR 1.14, 95% CI 1.12-1.16, P < 0.001) was an independent predictor of Gleason score ≥7 prostate cancer on prostate biopsy. The proportion of interval prostate cancer diagnosed in-between the screening rounds was not significantly different.

CONCLUSION:

Irrespective of the FH status, the current PSA-based screening setting detects the majority of aggressive prostate cancers and missed only a minority of interval cancers with a 4-year screening algorithm. Our results suggest that men with a positive FH are at increased risk of low-grade but not aggressive prostate cancer.

KEYWORDS:

positive family history; prostate cancer aggressiveness; prostate cancer screening; prostate-specific antigen; screening intensity

PMID:
26332304
PMCID:
PMC4955666
DOI:
10.1111/bju.13310
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center